Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2023 | Switching from S1Ps or HETs to DRF: results from the EVOLVE-MS-1 study

Barry Singer, MD, The MS Center for Innovations in Care, St. Louis, MO, discusses the results of the EVOLVE-MS-1 (NCT02634307) trial, an open-label Phase III study that evaluated safety, tolerability, and efficacy of diroximel fumarate (DRF) over 96 weeks in adults with relapsing-remitting multiple sclerosis (MS). This analysis assessed patients who switched from sphingosine-1-phosphate receptor modulators (S1P) or high-efficacy therapies (HET) to DRF. Patients switching from S1Ps or HETs to DRF had improved clinical and radiological outcomes and significant reductions in annualized relapse rates. These initial data support that switching to DRF may be an option for patients previously treated with S1P/HET. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


BS has received research grant support from AbbVie, Biogen, Bristol Myers Squibb, Greenwich Biosciences, Novartis and Sanofi and consulting and/or speaking fees from Alexion, Biogen, Bristol Myers Squibb, Cigna, Cycle, EMD Serono, Genentech, Horizon, Janssen, Novartis, Octave Bioscience, Roche, Sanofi and TG Therapeutics.